Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Stryker (SYK) to $365 from $400 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Insulet appoints Panos as Chief Commercial Officer
- Stryker restores most manufacturing following cyberattack, Bloomberg says
- Stryker Addresses and Contains Recent Cybersecurity Incident
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- Stryker cyberattack leads to some surgery delays, Bloomberg reports